This international discrete choice experiment explored treatment preferences among people living with IDH-mutant grade 2 glioma across four countries. Patients prioritised gains in survival but were also strongly influenced by risks of treatment side effects and future impacts on work and everyday activities, highlighting the importance of incorporating patient preferences into treatment decision-making.
Use of PLEX, IVIg, and SCIg as maintenance therapy in myasthenia gravis: unmet evidence needs and real-world data from the Vitaccess Real MG Registry
Larkin M, Amini F, Fellows A, Bagshaw E, Hayes A, Ward E (AANEM, 2026)



